Table 1. Vaccine formulations in... | American Society of Hematology

Table 1.

Vaccine formulations in development for non-Hodgkin lymphomas.

Vaccine formulation	Starting material	Production time	Target tumor antigen(s)	Phase of clinical development	Potential applicability	References
Idiotype-based	FNA or core biopsy		Tumor-specific Well-defined		B-cell malignancies
Id protein-KLH		> 2 mo		Phase 3		10,15–17,23,30
Id protein-DC		> 2 mo		Phase 2		22
DNA		< 1 mo		Phase 1		37,38,50
Membrane proteoliposome	Excisional biopsy	< 1 mo	Multiple Undefined	Phase 1	Multiple malignancies	39,40
Tumor-cell based	Excisional biopsy		Multiple Undefined		Multiple malignancies
GM-CSF transduced		< 1 mo		Phase 2		41
CD40 activated		< 1 mo		Phase 1		42
HSP-96		< 1 mo		Phase 1		45

Vaccine formulation	Starting material	Production time	Target tumor antigen(s)	Phase of clinical development	Potential applicability	References
Idiotype-based	FNA or core biopsy		Tumor-specific Well-defined		B-cell malignancies
Id protein-KLH		> 2 mo		Phase 3		10,15–17,23,30
Id protein-DC		> 2 mo		Phase 2		22
DNA		< 1 mo		Phase 1		37,38,50
Membrane proteoliposome	Excisional biopsy	< 1 mo	Multiple Undefined	Phase 1	Multiple malignancies	39,40
Tumor-cell based	Excisional biopsy		Multiple Undefined		Multiple malignancies
GM-CSF transduced		< 1 mo		Phase 2		41
CD40 activated		< 1 mo		Phase 1		42
HSP-96		< 1 mo		Phase 1		45